Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
- PMID: 18235114
- DOI: 10.1200/JCO.2007.14.0285
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
Abstract
Purpose: No primary lesion is identified in 10% to 20% of patients presenting with palpable evidence of regional metastatic melanoma. Because the prognostic significance of unknown primary melanoma (MUP) is unclear, we compared clinical outcomes of patients with MUP and known primary melanoma (MKP) with regional nodal metastases.
Patients and methods: We reviewed our 13,000-patient prospective melanoma database (1971 through 2005) to identify patients managed with regional lymphadenectomy for palpable nodal metastases from MUP or MKP. Multivariate analysis identified prognostic factors significant for survival. MUP and MKP were then matched by significant covariates. Overall survival (OS) was estimated by Kaplan-Meier method and compared by log-rank analysis.
Results: Multivariate analysis of data from 1,571 study patients identified four significant covariates associated with worse prognosis: age >or= 60 years (hazard ratio [HR] = 1.294; P = .0017), male sex (HR = 1.335; P = .0004), nodal tumor burden >or= one (HR = 1.256; P < .0001), and known primary (HR = 1.507; 95% CI, 1.220 to 1.862; P = .0001). Five-year OS was significantly higher for 262 patients with MUP than for 1,309 patients with MKP (55% +/- 6% v 44% +/- 3%; P = .0021). Computerized matching of MUP and MKP by four significant covariates (age, sex, nodal tumor burden, and decade of diagnosis) yielded 221 matched pairs. Median and 5-year OS rates were 165 months and 58% +/- 7%, respectively, for MUP as compared with 34 months and 40% +/- 7%, respectively, for MKP (P = .0006).
Conclusion: Lymphadenectomy is effective for nodal metastasis from MUP. The significantly better postoperative survival for MUP versus MKP suggests a strong endogenous immune response against the primary melanoma. Immunologic studies to identify cell-mediated and antibody components of this response may lead to new approaches for determining melanoma prognosis and treatment.
Comment in
-
Different natural course of disease in patients with melanoma.J Clin Oncol. 2009 Feb 20;27(6):998; author reply 999. doi: 10.1200/JCO.2008.20.5666. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164201 No abstract available.
Similar articles
-
Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.Ann Surg Oncol. 2014 Sep;21(9):3108-16. doi: 10.1245/s10434-014-3679-5. Epub 2014 May 7. Ann Surg Oncol. 2014. PMID: 24802907 Clinical Trial.
-
Melanoma without a detectable primary site with metastases to lymph nodes.Dermatol Surg. 2010 Jun;36(6):868-76. doi: 10.1111/j.1524-4725.2010.01562.x. Epub 2010 May 7. Dermatol Surg. 2010. PMID: 20482725
-
Metastatic melanoma to lymph nodes in patients with unknown primary sites.Cancer. 2006 May 1;106(9):2012-20. doi: 10.1002/cncr.21835. Cancer. 2006. PMID: 16568458
-
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.Oncology. 2017;93(4):249-258. doi: 10.1159/000478050. Epub 2017 Jul 27. Oncology. 2017. PMID: 28746931 Free PMC article. Review.
-
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.Melanoma Res. 2005 Feb;15(1):77-82. doi: 10.1097/00008390-200502000-00013. Melanoma Res. 2005. PMID: 15714125 Review.
Cited by
-
CD45/CD8 Myeloid Histioid Antigen and Plasma Cell Antibody Immune Response in a Case of Malignant Melanoma.N Am J Med Sci. 2012 Oct;4(10):507-9. doi: 10.4103/1947-2714.102006. N Am J Med Sci. 2012. PMID: 23112977 Free PMC article.
-
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.J Immunother Cancer. 2022 Jan;10(1):e004310. doi: 10.1136/jitc-2021-004310. J Immunother Cancer. 2022. PMID: 35074904 Free PMC article. Clinical Trial.
-
Treatment of Regional Metastatic Melanoma of Unknown Primary Origin.Cancers (Basel). 2015 Aug 10;7(3):1543-53. doi: 10.3390/cancers7030849. Cancers (Basel). 2015. PMID: 26266423 Free PMC article.
-
Proton beam therapy for cervical lymph node metastasis in an octogenarian with melanoma of unknown primary: a case report.Int Cancer Conf J. 2023 Feb 1;12(2):160-165. doi: 10.1007/s13691-023-00597-8. eCollection 2023 Apr. Int Cancer Conf J. 2023. PMID: 36896196 Free PMC article.
-
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.PLoS One. 2013 Apr 29;8(4):e63137. doi: 10.1371/journal.pone.0063137. Print 2013. PLoS One. 2013. PMID: 23638183 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical